Novopharm takes writedown on drug development delay
Article Abstract:
Novopharm Biotech Inc has suspended the development of a protein inhibitor known as its GPI-2A antisense product. The company said the suspension was due to the unanticipated side effects with the drug delivery system, pills or injections in the Phase 1 trial. Novopharm added that any systemically administered antisense product will not be effective without a drug delivery system. The company is also refocusing its product development efforts to on products with the most potential for commercialization.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
AltaRex says ovarian cancer drug results positive
Article Abstract:
AltaRex Corp has announced a significant improvement in survival rates for its OvaRex drug for treating ovarian cancer. The company reported a five-year survival rate of 40.7% compared with 11.4% in control group of patients who are receiving chemotherapy. The study, which was conducted betweem 1989 and 1994, also showed that the drug induced immune responses specifically against ovarian cancer cells.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Drug Royalty eyes healthy returns. IcePro shoots to score as one-stop rink supplier. First Place Tower pursues new debt plan
- Abstracts: Drugmakers have healthy outlook. Small firms can bank on Web. Inventive pilot sells safety breakthrough
- Abstracts: Merger makes sense to coal rivals. Westlinks takes on oil patch players. Sunoma going public to shed debt, raise capital
- Abstracts: Brewing up a plan. Amway takes aim at Web
- Abstracts: Pratt jobs headed south. Quebec blasts Ottawa on airline proposal. Firm helped by Ottawa cuts 900 jobs